中等度から重度のアトピー性皮膚炎の治療における単独または併用療法の有効性と安全性を評価する研究

基本情報

NCT ID

NCT06718101

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

80

治験依頼者名

AbbVie

概要

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Sub-Study 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of subcutaneous (SC) injections of lutikizumab every other week for a total of 52 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)